AIMS: This study aimed to evaluate incidence and correlates for low platelet count after transcatheter aortic valve replacement (TAVR) and to determine a possible association between acquired thrombocytopenia and clinical outcomes. METHODS AND RESULTS: Patients undergoing TAVR from two medical centres were included in the study. They were stratified according to nadir platelet count post procedure: no/mild thrombocytopenia, ≥100 × 10(9)/L; moderate, 50-99 × 10(9)/L; and severe, <50 × 10(9)/L. A total of 488 patients composed of the study population (age 84.7 ± 7.5 years). At a median time of 2 days after TAVR, 176 patients (36.1%) developed significant thrombocytopenia: 149 (30.5%) moderate; 27 patients (5.5%) severe. Upon discharge, the vast majority of patients (90.2%) had no/mild thrombocytopenia. Nadir platelet count <50 × 10(9)/L was highly specific (96.3%), and a count <150 × 10(9)/L highly sensitive (91.2%), for predicting 30-day death (C-statistic 0.76). Patients with severe acquired thrombocytopenia had a significantly higher mortality rate at 1 year (66.7% for severe vs. 16.0% for no/mild vs. 20.1% for moderate; P < 0.001). In multivariate logistic regression, severe thrombocytopenia was independently associated with 1-year mortality (hazard ratio 3.44, CI: 1.02-11.6; P = 0.046). CONCLUSIONS: Acquired thrombocytopenia was common after TAVR and was mostly resolved at patient discharge. The severity of thrombocytopenia after TAVR could be used as an excellent, easily obtainable, marker for worse short- and long-term outcomes after the procedure. Published on behalf of the European Society of Cardiology. All rights reserved.
AIMS: This study aimed to evaluate incidence and correlates for low platelet count after transcatheter aortic valve replacement (TAVR) and to determine a possible association between acquired thrombocytopenia and clinical outcomes. METHODS AND RESULTS:Patients undergoing TAVR from two medical centres were included in the study. They were stratified according to nadir platelet count post procedure: no/mild thrombocytopenia, ≥100 × 10(9)/L; moderate, 50-99 × 10(9)/L; and severe, <50 × 10(9)/L. A total of 488 patients composed of the study population (age 84.7 ± 7.5 years). At a median time of 2 days after TAVR, 176 patients (36.1%) developed significant thrombocytopenia: 149 (30.5%) moderate; 27 patients (5.5%) severe. Upon discharge, the vast majority of patients (90.2%) had no/mild thrombocytopenia. Nadir platelet count <50 × 10(9)/L was highly specific (96.3%), and a count <150 × 10(9)/L highly sensitive (91.2%), for predicting 30-day death (C-statistic 0.76). Patients with severe acquired thrombocytopenia had a significantly higher mortality rate at 1 year (66.7% for severe vs. 16.0% for no/mild vs. 20.1% for moderate; P < 0.001). In multivariate logistic regression, severe thrombocytopenia was independently associated with 1-year mortality (hazard ratio 3.44, CI: 1.02-11.6; P = 0.046). CONCLUSIONS: Acquired thrombocytopenia was common after TAVR and was mostly resolved at patient discharge. The severity of thrombocytopenia after TAVR could be used as an excellent, easily obtainable, marker for worse short- and long-term outcomes after the procedure. Published on behalf of the European Society of Cardiology. All rights reserved.
Authors: Travis R Sexton; Eric L Wallace; Amy Chen; Richard J Charnigo; Hassan K Reda; Khaled M Ziada; John C Gurley; Susan S Smyth Journal: J Thromb Thrombolysis Date: 2016-04 Impact factor: 2.300
Authors: Jörn A Karhausen; Alan M Smeltz; Igor Akushevich; Mary Cooter; Mihai V Podgoreanu; Mark Stafford-Smith; Susan M Martinelli; Manuel L Fontes; Miklos D Kertai Journal: Anesth Analg Date: 2017-10 Impact factor: 5.108
Authors: Homam Ibrahim; Eleonora Vapheas; Binita Shah; Ahmad AlKhalil; Michael Querijero; Hasan Jilaihawi; Peter Neuburger; Cezar Staniloae; Mathew R Williams Journal: Catheter Cardiovasc Interv Date: 2019-05-06 Impact factor: 2.692
Authors: Renato C de Souza; Leonardo Paim; Guilherme Viotto; Joaquim Aprigio; Lucas L Araújo; Henrique Ribeiro; Roney O Sampaio; Flavio Tarasoutchi; Pablo M A Pomerantzeff; José Honório Palma; Fabio B Jatene Journal: Braz J Cardiovasc Surg Date: 2018 Jul-Aug